Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older
Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%). Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated an rVE of 27.4%.
'Today's strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults. The severity of this past flu season underscores the need for more effective vaccines,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines.'
In a previous Phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine. [1]
According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work. [3]
P304 ( NCT06602024 ) is a Phase 3, randomized, observer-blind, active-controlled, case-driven, pivotal efficacy, immunogenicity and safety study. The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months.
Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. [4] The majority of solicited adverse reactions (SARs) were mild. Injection site pain was the most common local SAR, and fatigue, headache and myalgia were the most common systemic SARs reported. There were no significant differences between the groups in the rates of unsolicited adverse events, serious adverse events, or adverse events of special interest.
Moderna plans to present these data at an upcoming medical conference and submit for peer-reviewed publication. The Company will engage with regulators on filing submissions for mRNA-1010.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's engagement with regulators on filing submissions for its standalone flu vaccine candidate; and the efficacy, safety and tolerability of mRNA-1010. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov . Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
18 minutes ago
- Bloomberg
SNAP Cuts in Big Tax Bill Will Hit a Lot of Trump Voters Too
President Donald Trump's allies love to talk about the food we're eating here in the US: too sugary, too processed, too artificially dyed. What they're not talking about, though, is how many Americans don't have enough of it, whether it's healthy or not. If the Republicans get their way, the number of them will only go up. Exactly how the right-leaning majorities in the House and Senate will cut the Supplemental Nutrition Assistance Program, more commonly known as SNAP, is being negotiated. But their intentions are clear: Shrink its reach, reduce the benefits of the people still on it, and leave it to the states to take the blame.
The Hill
27 minutes ago
- The Hill
Republicans muscle through ‘big, beautiful' voting marathon
Thank you for signing up! Subscribe to more newsletters here It's Monday. It's a short holiday week, but man does Congress know how to keep things busy! In today's issue: Senate Republicans have begun their marathon vote-a-rama to pass President Trump's legislative agenda, a grueling process ahead of their self-imposed July 4 deadline. How's it going?: Senate Majority Leader John Thune (R-S.D.) declined to say this morning whether Republicans have the votes. 'Hopefully we'll know soon enough, right?' he said with a laugh. 'This may go a while.' 😅 💻 Watch the live vote-a-rama Will it pass?: Republicans can lose no more than three votes — and two of those 'no' votes are already spoken for: Sens. Thom Tillis (N.C.) and Rand Paul (Ky.) are hard nos. Who to keep your eye on: Sens. Susan Collins (R-Maine) and Lisa Murkowski (R-Alaska). They both voted to advance the bill Saturday but haven't said if they will ultimately vote for the bill. FWIW, Republicans see Murkowski as a more likely 'yes' vote for them. What we're watching: A group of conservatives want more Medicaid cuts, but Republicans have very little room for error. Trump warned conservatives not to go 'too crazy' with 'cost cutting.' How the vote-a-rama works: Senators can offer an unlimited number of amendments related to the bill — with a quick opportunity for debate and vote. This process can stretch for many hours. The Senate worked late into last night and could have begun the vote-a-rama overnight, but GOP leaders opted to pause and begin again at 9 a.m. today, giving lawmakers time to rest up. 🗨️ Follow today's live blog — there are a lot of moving parts, so I find this particularly helpful on days like today. ➤ SIGHTS AND SOUNDS FROM THE SENATE FLOOR: Collins's amendment to raise taxes on the ultra-wealthy: Collins filed an amendment to raise the marginal tax rate on Americans who earn more than $25 million a year. If only we had microphones to overhear: Several reporters noticed Sen. Thom Tillis (R-N.C.), who broke with GOP leadership and opposes the overall bill, chatting with former Senate GOP Leader Mitch McConnell (Ky.). One reporter noticed the two of them walking toward the chamber exit together. 📸 Photo 📸 Competing Senate floor charts ➤ WHAT HAPPENS IF THE SENATE PASSES THE BILL?: If it clears the Senate today, it will return to the House to see if the representatives agree to the changes. The Hill's Mychael Schnell reports it would go to the House Rules Committee before coming to the floor for a vote. GOP leaders said the first votes could happen Wednesday morning. ➤ WHAT MADE IT INTO THE BILL?: Senate Republicans unveiled most of the legislative text late Friday night. The biggest change from the House bill: The Senate version includes steeper cuts to Medicaid. The Hill's Al Weaver published a helpful breakdown of what's in the bill. 🔎 Read the bill The costs: Tax cuts are by far the most expensive part of this bill. There are also funds for defense and homeland security. The savings: Medicaid cuts are the biggest chunk of savings to fund those cuts, followed by green energy cuts, student loans and food benefits, per The New York Times. 📊 Helpful chart comparing the bill's spending and saving ➤ WHO ELSE WATCHED C-SPAN ON SATURDAY NIGHT?!: Senators worked through the weekend to massage both the bill and the caucus to vote 'yes' before their self-imposed July 4 deadline. The Senate clerks even read all 940 pages of the bill aloud, which took nearly 16 hours. At one point Sunday, Trump called for Republicans to overrule the parliamentarian's order. But keep in mind that overruling the parliamentarian opens a can of worms. It gets uncomfortably close to ignoring the filibuster. Sen. Thom Tillis (R-N.C.) opposed a key procedural vote on President Trump's 'big, beautiful bill,' arguing the cuts to Medicaid 'will hurt people who are eligible and qualified' to receive the benefit. The Medicaid cuts would cost more than $30 billion for his state, and Tillis bashed Trump for betraying 'the very promise' he made when he pledged not to interfere with Americans' Medicaid benefits. 📹 Watch Tillis explain his 'no' vote This sent Trump into a rage over the weekend, relentlessly attacking Tillis in social media posts. The president even said he would back a primary challenge to boot Tillis from office. So Tillis basically said 'hold my beer': He abruptly announced Sunday that he wouldn't seek reelection in the midterms. This sent a shockwave through Washington. His seat is widely considered to be one of the hardest for Republicans to defend in 2026. That will only get tougher without Tillis as the incumbent. Sen. Mitch McConnell (R-Ky.), the former Senate GOP leader, called Tillis's retirement a 'setback' for Republicans. Tidbit: Tillis texted Trump on Saturday to give him a heads-up about his decision not to run for reelection. This text was sent seven minutes before Trump posted that he would find a primary challenger, according to the text that was viewed by The Hill. Another Trump may be interested in the job: A source confirmed to The Hill that Lara Trump, the president's daughter-in-law and former co-chair of the Republican National Committee (RNC), is considering running for Tillis's seat. NOTUS first reported that she is 'seriously considering' a Senate bid. ➤ JUST IN: Rep. DonBacon (R-Neb.) officially announced this morning that he would not seek reelection in 2026, opening up what is likely to be a competitive race for Nebraska's 2nd Congressional District. The Hill's JuliaManchester has more here. 'The Supreme Court on Monday agreed to take up Vice President Vance and GOP committees' bid to strike down federal limits on political parties' spending made in coordination with campaigns,' reports The Hill's Zach Schonfeld. This could be a major campaign finance battle next term. Read more on the case: 'Supreme Court to hear Vance, GOP effort to strike down campaign finance provision' ➤ THE COURT SAID 'NO' TO A FEW CASES: TikTok and free speech: 'The Supreme Court on Monday declined to hear a Massachusetts teacher's First Amendment challenge concerning her termination for making and reposting antitransgender TikToks.' Read more American Airlines: 'The Supreme Court on Monday turned away American Airlines's bid to reverse a lower court ruling invalidating the carrier's alliance with JetBlue in the Northeast.' Read more ➤ HOLIDAY WEEK TIDBIT: The White House put up a big American flag ahead of the Fourth of July. 📸 Photo The Trump administration has revoked U.S. visas for members of rap-punk duo Bob Vylan after the group made inflammatory remarks about Israel. What happened?: Vylan led concertgoers a 'death, death to the IDF' chant at the U.K.'s Glastonbury Festival over the weekend, referring to the Israel Defense Forces. Keep in mind: The group was scheduled to perform in Boston, New York City and Washington, D.C., this fall. This incident has gotten a lot of attention. British Prime Minister Keir Starmer called the Glastonbury chants 'appalling hate speech,' and the BBC apologized for continuing to airing the show after the incident. Two firefighters were shot and killed and another was injured in Idaho on Sunday afternoon after responding to a fire that was intentionally set by a gunman. A local sheriff called it a 'total ambush,' reports The Associated Press. The suspect, who police believe acted alone, is presumed dead after a male's body, along with a weapon, was found near the scene. 📰 Read more here The House is out. The Senate is in. President Trump is in Washington. (All times EST) 1 p.m.: White House press secretary Karoline Leavitt briefs reporters. 💻 Livestream 2:30 p.m.: Trump signs executive orders. 🍹 Celebrate: Today is National Mai Tai Day! 📞 Want your blood to boil?: Ever experience a dropped call while on the phone with customer service? The Atlantic's Chris Colin reports that 'it was on purpose.' The gist: 'Endless wait times and excessive procedural fuss—it's all part of a tactic called 'sludge.'' 🥞 Cracker Barrel is getting a 'glow-up': The old-timey Southern restaurant Cracker Barrel is 'decluttering the décor,' reports The Wall Street Journal. 'Cracker Barrel Fans Mourn the Loss of That Old-Timey Feeling,' WSJ's Jennifer Williams writes. ✂️ The year of the bob: The blunt bob haircut is having a moment, writes The Washington Post's Samantha Chery. Sofia Richie, Jenna Bush Hager and Megan Thee Stallion have all recently chopped their hair. And to brighten your Monday, meet this glamorous diva. Thanks for reading! Check out more newsletters from The Hill here. See you next time.
The Hill
27 minutes ago
- The Hill
Experimental Moderna flu shot more effective than approved vaccine, company says
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company's mRNA-1010 flu vaccine's efficacy was nearly 27 percent higher for adults 50 and older than a currently available shot. The shot also showed strong efficacy against each of the major influenza strains in the shot including A/H1N1, A/H3N2 and the B/Victoria lineages. Efficacy appeared consistently strong across age groups, flu vaccination status and among people with various risk factors, Moderna said in a statement. The trial enrolled more than 40,800 adults 50 and older from 11 countries. 'The severity of this past flu season underscores the need for more effective vaccines,' said Stephane Bancel, chief executive officer of Moderna. 'An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines.' Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to the CDC. At least 600,000 Americans were hospitalized last year due to flu-related illness, agency data show. According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work After consulting the Food and Drug Administration, Moderna withdrew its application last month for a dual flu and COVID-19 vaccine for adults 50 years old and older. Moderna plans to resubmit the application for the combination vaccine with the new data, according to CNBC. The company also plans to submit the data on the mRNA-1010 shot to U.S. regulators this year.
